Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.

<h4>Background</h4>Human cathelicidin LL-37 is a cationic antimicrobial peptide (AMP) which possesses a variety of activities including the ability to neutralise endotoxin. In this study, we investigated the role of LPS neutralisation in mediating LL-37's ability to inhibit Pseudomo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Aaron Scott, Sinéad Weldon, Paul J Buchanan, Bettina Schock, Robert K Ernst, Danny F McAuley, Michael M Tunney, Chris R Irwin, J Stuart Elborn, Clifford C Taggart
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2011
Materias:
R
Q
Acceso en línea:https://doaj.org/article/d935bca1e2e944898c006e6fb0657907
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d935bca1e2e944898c006e6fb0657907
record_format dspace
spelling oai:doaj.org-article:d935bca1e2e944898c006e6fb06579072021-11-18T07:36:15ZEvaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.1932-620310.1371/journal.pone.0026525https://doaj.org/article/d935bca1e2e944898c006e6fb06579072011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22028895/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Human cathelicidin LL-37 is a cationic antimicrobial peptide (AMP) which possesses a variety of activities including the ability to neutralise endotoxin. In this study, we investigated the role of LPS neutralisation in mediating LL-37's ability to inhibit Pseudomonas aeruginosa LPS signalling in human monocytic cells.<h4>Methodology/principal findings</h4>Pre-treatment of monocytes with LL-37 significantly inhibited LPS-induced IL-8 production and the signalling pathway of associated transcription factors such as NF-κB. However, upon removal of LL-37 from the media prior to LPS stimulation, these inhibitory effects were abolished. These findings suggest that the ability of LL-37 to inhibit LPS signalling is largely dependent on extracellular LPS neutralisation. In addition, LL-37 potently inhibited cytokine production induced by LPS extracted from P. aeruginosa isolated from the lungs of cystic fibrosis (CF) patients. In the CF lung, polyanionic molecules such as glycosaminoglycans (GAGs) and DNA bind LL-37 and impact negatively on its antibacterial activity. In order to determine whether such interactions interfere with the LPS neutralising ability of LL-37, the status of LL-37 and its ability to bind LPS in CF sputum were investigated. Overall our findings suggest that in the CF lung, the ability of LL-37 to bind LPS and inhibit LPS-induced IL-8 production is attenuated as a result of binding to DNA and GAGs. However, LL-37 levels and its concomitant LPS-binding activity can be increased with a combination of DNase and GAG lyase (heparinase II) treatment.<h4>Conclusions/significance</h4>Overall, these findings suggest that a deficiency in available LL-37 in the CF lung may contribute to greater LPS-induced inflammation during CF lung disease.Aaron ScottSinéad WeldonPaul J BuchananBettina SchockRobert K ErnstDanny F McAuleyMichael M TunneyChris R IrwinJ Stuart ElbornClifford C TaggartPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 10, p e26525 (2011)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Aaron Scott
Sinéad Weldon
Paul J Buchanan
Bettina Schock
Robert K Ernst
Danny F McAuley
Michael M Tunney
Chris R Irwin
J Stuart Elborn
Clifford C Taggart
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
description <h4>Background</h4>Human cathelicidin LL-37 is a cationic antimicrobial peptide (AMP) which possesses a variety of activities including the ability to neutralise endotoxin. In this study, we investigated the role of LPS neutralisation in mediating LL-37's ability to inhibit Pseudomonas aeruginosa LPS signalling in human monocytic cells.<h4>Methodology/principal findings</h4>Pre-treatment of monocytes with LL-37 significantly inhibited LPS-induced IL-8 production and the signalling pathway of associated transcription factors such as NF-κB. However, upon removal of LL-37 from the media prior to LPS stimulation, these inhibitory effects were abolished. These findings suggest that the ability of LL-37 to inhibit LPS signalling is largely dependent on extracellular LPS neutralisation. In addition, LL-37 potently inhibited cytokine production induced by LPS extracted from P. aeruginosa isolated from the lungs of cystic fibrosis (CF) patients. In the CF lung, polyanionic molecules such as glycosaminoglycans (GAGs) and DNA bind LL-37 and impact negatively on its antibacterial activity. In order to determine whether such interactions interfere with the LPS neutralising ability of LL-37, the status of LL-37 and its ability to bind LPS in CF sputum were investigated. Overall our findings suggest that in the CF lung, the ability of LL-37 to bind LPS and inhibit LPS-induced IL-8 production is attenuated as a result of binding to DNA and GAGs. However, LL-37 levels and its concomitant LPS-binding activity can be increased with a combination of DNase and GAG lyase (heparinase II) treatment.<h4>Conclusions/significance</h4>Overall, these findings suggest that a deficiency in available LL-37 in the CF lung may contribute to greater LPS-induced inflammation during CF lung disease.
format article
author Aaron Scott
Sinéad Weldon
Paul J Buchanan
Bettina Schock
Robert K Ernst
Danny F McAuley
Michael M Tunney
Chris R Irwin
J Stuart Elborn
Clifford C Taggart
author_facet Aaron Scott
Sinéad Weldon
Paul J Buchanan
Bettina Schock
Robert K Ernst
Danny F McAuley
Michael M Tunney
Chris R Irwin
J Stuart Elborn
Clifford C Taggart
author_sort Aaron Scott
title Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
title_short Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
title_full Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
title_fullStr Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
title_full_unstemmed Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
title_sort evaluation of the ability of ll-37 to neutralise lps in vitro and ex vivo.
publisher Public Library of Science (PLoS)
publishDate 2011
url https://doaj.org/article/d935bca1e2e944898c006e6fb0657907
work_keys_str_mv AT aaronscott evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
AT sineadweldon evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
AT pauljbuchanan evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
AT bettinaschock evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
AT robertkernst evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
AT dannyfmcauley evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
AT michaelmtunney evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
AT chrisrirwin evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
AT jstuartelborn evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
AT cliffordctaggart evaluationoftheabilityofll37toneutraliselpsinvitroandexvivo
_version_ 1718423254023012352